跳至主要内容
临床试验/NCT07023003
NCT07023003招募中4 期

Postpartum Evaluation of Antihypertensives for Control of Hypertension: A Randomized Controlled Equivalence Study

Nebraska Methodist Health System1 个研究点 分布在 1 个国家目标入组 850 人开始时间: 2025年7月11日最近更新:
干预措施
相关药物

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
850
试验地点
1
主要终点
Hospital Readmission

研究概览

简要总结

This is an open label, randomized controlled trial designed to compare nifedipine and enalapril in the management of postpartum hypertension. This is an equivalence study- meaning it is not expected one medication is better than the other. Nifedipine has been shown to be better than another common blood pressure medicine, labetalol, for postpartum hypertension but enalapril which is also used worldwide to manage blood pressure postpartum, has not yet been evaluated or compared to nifedipine.

Investigators will identify and offer enrollment to women who are admitted for delivery with documented hypertension- participants with either chronic hypertension or pregnancy related hypertension will be included. Our hypothesis is both medications are safe and effective in managing blood pressure and preventing readmission for hypertensive complications during the postpartum period so evaluating the rate of readmission is the primary goal of the study.

The only intervention of the trial will be to assign which medication the participant starts taking. Any decisions after that point- stopping medication, changing doses, additional medications, discharge from the hospital, etc, will all be at the discretion of the participant's primary provider.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • admitted for delivery by cesarean or vaginal delivery
  • 24 weeks gestation or greater
  • Pregnancy related hypertension(HTN) or chronic hypertension. Pregnancy related hypertension will be defined during the study as either a systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg on two occasions at least 4 hours apart. This definition is consistent with the ACOG definition for pregnancy related HTN in patients without CHTN.

排除标准

  • Absolute contraindication to either nifedipine or enalapril Relative contraindications will be reviewed with PI.
  • Persistent HR <60 or >110
  • Native language other than English

研究组 & 干预措施

Nifedipine XR

Active Comparator

Patients will be randomized to receive nifedipine 30mg XR BID. Any additional changes in treatment will be at the discretion of their provider.

干预措施: Nifedipine 30mg XL BID (Drug)

Enalapril 10mg QD

Experimental

Patients will be administered 10mg enalapril daily. Any additional intervention or changes in management of their hypertension will be at the discretion of their primary provider.

干预措施: Enalapril 10mg QD (Drug)

结局指标

主要结局

Hospital Readmission

时间窗: Within 6 weeks of delivery

Number of participants meeting criteria for hospital admission.

次要结局

未报告次要终点

研究者

发起方
Nebraska Methodist Health System
申办方类型
Other
责任方
Principal Investigator
主要研究者

Todd Lovgren

Principal Investigator

Nebraska Methodist Health System

研究点 (1)

Loading locations...

相似试验